Drug Trial Radar · NCT02941926
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
Last checked: Nov 19, 2026Latest source record: Oct 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,246
Actual
Start
Nov 30, 2016
Primary completion
Nov 8, 2019
Study completion Nov 9, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer and no prior hormonal treatment for advanced disease..
Conditions
- Breast Cancer
Interventions
RibociclibDrug
Ribociclib was centrally supplied to the investigators and administered orally once a day on days 1-21 of each 28 day cycle at a starting dose of 600 mg daily
LetrozoleDrug
Letrozole was procured locally and administered orally once a day on a continuous daily schedule at a dose of 2.5 mg
GoserelinDrug
Goserelin was procured locally and administered in men and premenopausal women as an injectable subcutaneous implant administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 3.6 mg (cycle = 28 days)
LeuprolideDrug
Leuprolide was procured locally and administered in men and premenopausal women as an injectable intramuscular depot administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 7.5 mg (cycle= 28 days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) During Treatment With Ribociclib + Letrozole in the Core PhaseTime frame: From start of treatment up to 30 days after last treatment (for participants who did not enter to the Extension phase) or up to last treatment in the Core phase (for participants who entered the Extension phase), assessed up to approximately 33 months.
Locations
495 sites in 38 countries. Site status is shown where the registry gives one.
Alaska Cancer Research and Education Center
Anchorage, Alaska
Ironwood Cancer and Research Centers
Chandler, Arizona
Arizona Oncology Associates
Phoenix, Arizona
Arizona Oncology Associates Arizona Oncology Assoc. (2)
Tucson, Arizona
Highlands Oncology Group
Fayetteville, Arkansas
Beverly Hills Cancer Center
Beverly Hills, California
Pacific Shores Medical Group SC
Long Beach, California
USC Norris Cancer Center
Los Angeles, California
University of California Irvine UC Irvine (11)
Orange, California
Ventura County Hematology and Oncology
Oxnard, California
PCR Oncology
Pismo Beach, California
California Pacific Medical Center Onc Dept
San Francisco, California
Centura Health Research Center Centura Health Research Center
Denver, Colorado
Poudre Valley Hospital Poudre Valley Health System
Fort Collins, Colorado
Valley View Hospital Cancer Center
Glenwood Springs, Colorado
Florida Cancer Research Institute Dept of Oncology
Davie, Florida
Foundation for Sickle Cell Disease Research
Hollywood, Florida
Watson Clinic Center for Research 1730 Location
Lakeland, Florida
Mid Florida Hematology and Onc Ctr
Orange, Florida
Summit Cancer Care Summit Cancer Care (SC)
Savannah, Georgia
John D Archbold Memorial Hospital John D. Archbold Mem Hosp (4)
Thomasville, Georgia
Saint Alphonsus Regional Medical Center
Boise, Idaho
Stroger Cook County Hospital Division of Hematology & Onc
Chicago, Illinois
Joliet Oncology-Hematology Associates Presence Cancer Center
Joliet, Illinois
Mid Illinois Hematology Oncology Mid Illinois Hema/Onc (3)
Normal, Illinois
Alpha Med Physician Group, LLC
Tinley Park, Illinois
Indian Univ Health Goshen Center forCancer SC
Goshen, Indiana
Northwest Oncology
Munster, Indiana
June E. Nylan Cancer Center
Sioux City, Iowa
University of Kansas Medical Center University of Kansas Med Ctr 9
Kansas City, Kansas
Sarah Cannon at Overland Park Regional Medical Center
Overland Park, Kansas
John Ochsner Heart and Vascular Institute Clinical Trials
New Orleans, Louisiana
Northern Light Mercy Hospital SC
Portland, Maine
Greater Baltimore Medical Center Cancer Center Greater Baltimore Medical Ctr
Baltimore, Maryland
Maryland Oncology Hematology P A Columbia
Rockville, Maryland
Kaiser Permanente
Rockville, Maryland
Medical Faculty Assc Inc Medical Faculty Assc., Inc. (2
Washington DC, Maryland
Jackson Oncology Associates
Jackson, Mississippi
Nebraska Hematology-Oncology, P.C.
Lincoln, Nebraska
Nebraska Cancer Specialists Oncology Hematology West
Omaha, Nebraska
Showing 40 of 495 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.